Literature DB >> 30479741

Significant drug-drug interaction between warfarin and nafcillin.

Cynthia A King1, Kathleen M Babcock2, Rhianna J Godios2, Benjamin S King3.   

Abstract

Nafcillin, a beta-lactam semisynthetic penicillin, is highly resistant to penicillinase and is similar to other penicillins except that it is primarily metabolized in the liver. It is believed that nafcillin causes CYP3A4 enzyme induction which decreases warfarin's half-life. The onset of CYP3A4 induction by nafcillin occurs within the first 7 days, but maximal effects may take up to 2 weeks. Once nafcillin is discontinued, the effects persist for several weeks. A 79-year-old male with a history of atrial fibrillation and a 53-year-old male with a history of recurrent venous thromboembolism required significantly higher weekly warfarin doses during courses of nafcillin therapy. Both patients required a 2.5-3.5-fold increase from their baseline weekly warfarin dose to achieve therapeutic international normalized ratios (INRs) while on nafcillin. Traditional protocol-driven warfarin management can result in suboptimal anticoagulation in patients on warfarin and nafcillin.

Entities:  

Keywords:  CYP 3A4 induction; drug interactions; nafcillin; subtherapeutic INR; warfarin

Year:  2018        PMID: 30479741      PMCID: PMC6243422          DOI: 10.1177/2042098618796186

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  18 in total

1.  Interaction of dicloxacillin with warfarin.

Authors:  Christopher S Lacey
Journal:  Ann Pharmacother       Date:  2004-03-30       Impact factor: 3.154

2.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

3.  Identifying Drug-Drug Interactions by Data Mining: A Pilot Study of Warfarin-Associated Drug Interactions.

Authors:  Peter Wæde Hansen; Line Clemmensen; Thomas S G Sehested; Emil Loldrup Fosbøl; Christian Torp-Pedersen; Lars Køber; Gunnar H Gislason; Charlotte Andersson
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-11-08

Review 4.  A review of enzyme induction of warfarin metabolism with recommendations for patient management.

Authors:  J S Cropp; H I Bussey
Journal:  Pharmacotherapy       Date:  1997 Sep-Oct       Impact factor: 4.705

5.  Change in International Normalized Ratio Among Patients Treated With Dicloxacillin and Vitamin K Antagonists.

Authors:  Anton Pottegård; Daniel P Henriksen; Kenneth G Madsen; Maja Hellfritzsch; Per Damkier; Tore B Stage
Journal:  JAMA       Date:  2015-07-21       Impact factor: 56.272

6.  Prosthetic heart valve thrombosis during dicloxacillin therapy.

Authors:  S Halvorsen; T Husebye; H Arnesen
Journal:  Scand Cardiovasc J       Date:  1999       Impact factor: 1.589

7.  Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium.

Authors:  P M Krstenansky; W N Jones; H S Garewal
Journal:  Clin Pharm       Date:  1987-10

Review 8.  Continuation of warfarin-nafcillin interaction during dicloxacillin therapy.

Authors:  A T Taylor; D C Pritchard; A O Goldstein; J L Fletcher
Journal:  J Fam Pract       Date:  1994-08       Impact factor: 0.493

Review 9.  Interaction between warfarin and nafcillin: case report and review of the literature.

Authors:  Karissa Y Kim; R J Frey; Kelly Epplen; Farzin Foruhari
Journal:  Pharmacotherapy       Date:  2007-10       Impact factor: 4.705

10.  A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.

Authors:  Kazuto Yasuda; Aarati Ranade; Raman Venkataramanan; Stephen Strom; Jonathan Chupka; Sean Ekins; Erin Schuetz; Kenneth Bachmann
Journal:  Drug Metab Dispos       Date:  2008-05-27       Impact factor: 3.922

View more
  2 in total

Review 1.  Drug Interactions Affecting Oral Anticoagulant Use.

Authors:  Philip L Mar; Rakesh Gopinathannair; Brooke E Gengler; Mina K Chung; Arturo Perez; Jonathan Dukes; Michael D Ezekowitz; Dhanunjaya Lakkireddy; Gregory Y H Lip; Mike Miletello; Peter A Noseworthy; James Reiffel; James E Tisdale; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2022-05-27

2.  Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.

Authors:  Morgan A Wambaugh; Steven T Denham; Magali Ayala; Brianna Brammer; Miekan A Stonhill; Jessica Cs Brown
Journal:  Elife       Date:  2020-05-05       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.